查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲全基因组和EXOME定序市场：按最终用户和国家分析和预测（2024-2033）
市场调查报告书
商品编码
1668769

欧洲全基因组和EXOME定序市场：按最终用户和国家分析和预测（2024-2033）

Europe Whole Genome and Exome Sequencing Market: Focus on End User and Country - Analysis and Forecast, 2024-2033
出版日期: | 出版商: BIS Research | 英文 57 Pages | 商品交期: 1-5个工作天内

价格

预计到 2033 年，欧洲全基因组和EXOME定序市场规模将从 2024 年的 5.49 亿美元达到 17.773 亿美元，预测期内的复合年增长率为 13.94%。

EXOME定序（WES）和全基因测序（WGS）是彻底改变欧洲基因分析的尖端基因组技术。 WGS 对整个基因组进行定序，包括转录区和非编码区域，而 WES 仅针对蛋白质编码外显子，其中包含大多数与疾病相关的突变。这些技术正在彻底改变临床诊断、个人化医疗和罕见疾病研究，推动医疗创新。随着技术不断进步、成本下降和应用范围不断扩大，WGS 和 WES 正成为欧洲基因体学的重要工具。

主要市场统计数据
预测期 2024-2033
2024 年评估 5.49亿美元
2033 年预测 17.773亿美元
复合年增长率 13.94％

由于个人化医疗需求的不断增长、临床诊断应用的不断增长以及基因组研究的不断改进，欧洲全基因组和EXOME定序市场正在显着增长。EXOME定序（WES）主要针对蛋白质转录区，大多数已知的疾病相关突变都存在于该区域，而全基因测序（WGS）则可以深入了解一个人的完整基因组成。这些技术正在透过促进早期疾病检测、精准医疗和更好地了解遗传疾病来改变医疗产业。

对 WGS 和 WES 的需求是由于癌症、神经系统疾病和罕见疾病的发生率不断上升，尤其是在临床和研究环境中。政府对基因组医学的资助和倡议以及生物技术公司和医疗机构之间的合作也推动了市场扩张。此外，定序技术的不断改进正在降低成本并使这些先进的工具更容易获得。

欧洲拥有严格的法律规范，确保资料准确性和患者安全，并处于基因组创新的前沿。肿瘤学、感染疾病研究和生殖医学领域应用的不断扩大也促进了市场的成长。随着基因测序的不断发展，它将在未来整个欧洲的精准医疗和生物医学研究中发挥关键作用。

市场区隔

细分 1：按最终用户

  • 製药和生物技术公司
  • 诊断实验室
  • 医院和诊所
  • 研究和学术机构
  • 其他的

细分2：按地区

  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 其他的

本报告研究了欧洲全基因组和EXOME定序市场，并提供了主要趋势的摘要、影响市场的因素的分析、法律制度、市场规模趋势和预测、各个细分市场和主要国家的详细分析、竞争格局以及主要企业的概况。

目录

执行摘要

范围和定义

第一章 产业展望

  • 市场趋势
    • 定序技术的创新
    • 市场上有大量无机成长活动
  • COVID-19 对市场的影响
  • 法律规范
    • 欧洲法律要求和框架
  • 供应链分析
  • 市场动态概览
    • 市场驱动因素
    • 市场限制
    • 市场机会

第二章 区域

  • 区域概况
  • 欧洲
    • 区域概况
    • 市场成长动力
    • 市场问题
    • 法国
    • 德国
    • 英国
    • 西班牙
    • 义大利
    • 荷兰
    • 其他的

第 3 章市场：竞争基准化分析与公司简介

  • 主要策略及发展
  • 企业市场占有率分析
  • 公司简介
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche Ltd
    • Oxford Nanopore Technologies plc
    • QIAGEN NV

第四章调查方法

Product Code: BHP2660SS

Introduction to Europe Whole Genome and Exome Sequencing Market

The Europe whole genome and exome sequencing market is projected to reach $1,777.3 million by 2033 from $549.0 million in 2024, growing at a CAGR of 13.94% during the forecast period 2024-2033. Exome sequencing (WES) and whole genome sequencing (WGS) are cutting-edge genomic technologies that are revolutionising genetic analysis in Europe. WGS decodes the entire genome, including coding and non-coding regions, while WES only targets protein-coding exons, which contain the majority of disease-related variants. These techniques are boosting healthcare innovation by revolutionising clinical diagnostics, personalised medicine, and rare disease research. As technology continues to advance, costs come down, and their applications expand, WGS and WES are becoming indispensable tools in European genomics.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2024 - 2033
2024 Evaluation$549.0 Million
2033 Forecast$1,777.3 Million
CAGR13.94%

The market for whole genome and exome sequencing in Europe is expanding significantly due to the growing demand for personalised medicine, growing adoption of clinical diagnostics, and improvements in genomic research. Exome sequencing (WES) concentrates on protein-coding regions, which are home to the majority of known disease-related variants, whereas whole genome sequencing (WGS) offers a thorough examination of a person's complete genetic composition. By facilitating early disease detection, precision treatment, and a better understanding of genetic disorders, these technologies are transforming the healthcare industry.

The need for WGS and WES has increased due to the rising incidence of cancer, neurological disorders, and rare diseases, especially in clinical and research settings. Market expansion is also being aided by government funding and initiatives for genomic medicine, as well as partnerships between biotech companies and healthcare organizations. Additionally, ongoing improvements in sequencing technology are reducing costs, making these advanced tools more accessible.

With stringent regulatory frameworks ensuring data accuracy and patient safety, Europe is at the forefront of genomic innovation. Expanding applications in oncology, infectious disease research, and reproductive health are also contributing to market growth. As genomic sequencing continues to evolve, it is set to play a crucial role in the future of precision medicine and biomedical research across Europe.

Market Segmentation

Segmentation 1: by End User

  • Pharmaceutical and Biotechnology Companies
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Research and Academic Institutes
  • Others

Segmentation 2: by Region

  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Netherlands
    • Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements and emerging applications in genome and exome sequencing, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Oxford Nanopore Technologies plc
  • QIAGEN N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Industry Outlook

  • 1.1 Market Trends
    • 1.1.1 Technological Innovations in the Sequencing Technology
    • 1.1.2 Numerous Inorganic Growth Activities in the Market
  • 1.2 COVID-19 Impact on Market
  • 1.3 Regulatory Framework
    • 1.3.1 Legal Requirements and Framework in Europe
  • 1.4 Supply Chain Analysis
  • 1.5 Market Dynamics Overview
    • 1.5.1 Market Drivers
      • 1.5.1.1 Growing Applications of Whole Genome and Exome Sequencing in Clinical Diagnostics
      • 1.5.1.2 Rising Demand for Personalized Medicine Influencing the Demand for Whole Genome and Exome Sequencing
      • 1.5.1.3 Lowering Costs and Increasing Accessibility of Genome Sequencing
      • 1.5.1.4 Ongoing Whole Genome Sequencing Government Initiatives around the World
    • 1.5.2 Market Restraints
      • 1.5.2.1 Privacy and Ethical Concerns due to Increased Risk of Security Breaches
    • 1.5.3 Market Opportunities
      • 1.5.3.1 Increasing Usage of Sequencing Technology in Emerging Markets

2 Region

  • 2.1 Regional Summary
  • 2.2 Europe
    • 2.2.1 Regional Overview
    • 2.2.2 Driving Factors for Market Growth
    • 2.2.3 Factors Challenging the Market
      • 2.2.3.1 By End User
    • 2.2.4 France
    • 2.2.5 Germany
    • 2.2.6 U.K.
    • 2.2.7 Spain
    • 2.2.8 Italy
    • 2.2.9 Netherlands
    • 2.2.10 Rest-of-Europe

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Key Strategies and Development
  • 3.2 Company Share Analysis
  • 3.3 Company Profiles
    • 3.3.1 Eurofins Scientific SE
      • 3.3.1.1 Overview
      • 3.3.1.2 Top Products
      • 3.3.1.3 Top Competitors
      • 3.3.1.4 Key Personnel
      • 3.3.1.5 Analyst View
    • 3.3.2 F. Hoffmann-La Roche Ltd
      • 3.3.2.1 Overview
      • 3.3.2.2 Top Products
      • 3.3.2.3 Top Competitors
      • 3.3.2.4 Key Personnel
      • 3.3.2.5 Analyst View
    • 3.3.3 Oxford Nanopore Technologies plc
      • 3.3.3.1 Overview
      • 3.3.3.2 Top Products
      • 3.3.3.3 Top Competitors
      • 3.3.3.4 Key Personnel
      • 3.3.3.5 Analyst View
    • 3.3.4 QIAGEN N.V.
      • 3.3.4.1 Overview
      • 3.3.4.2 Top Products
      • 3.3.4.3 Top Competitors
      • 3.3.4.4 Key Personnel
      • 3.3.4.5 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Whole Genome and Exome Sequencing Market (by Region), $Million, 2023, 2026, and 2033
  • Figure 2: Europe Whole Genome and Exome Sequencing Market (by End User), $Million, 2023, 2026, and 2033
  • Figure 3: Key Events to Keep Track of within the Whole Genome and Exome Sequencing Market
  • Figure 4: Value and Supply Chain Analysis, Whole Genome and Exome Sequencing Market
  • Figure 5: Analysis of Market Navigating Factors, 2023-2033
  • Figure 6: Key Clinical Applications of Whole Genome and Whole Exome Sequencing
  • Figure 7: Number of Research Papers Mentioning Personalized Medicine in PubMed, 2010-2023
  • Figure 8: Decreasing Genome Sequencing Costs
  • Figure 9: Map of a Few Recent and Ongoing Government-Funded National Genomic-Medicine Initiatives
  • Figure 10: Examples of Security Breaches in Whole Genome and Exome Sequencing
  • Figure 11: France Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 12: Germany Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 13: U.K. Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 14: Spain Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 15: Italy Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 16: Netherlands Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 17: Rest-of-Europe Whole Genome and Exome Sequencing Market, $Million, 2023-2033
  • Figure 18: Strategic Initiatives, January 2021-April 2024
  • Figure 19: Share of Strategic Initiatives, January 2021-April 2024
  • Figure 20: Whole Genome and Exome Sequencing Market, Company Revenue Share Analysis, 2023
  • Figure 21: Data Triangulation
  • Figure 22: Top-Down and Bottom-Up Approach
  • Figure 23: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Opportunities across Regions
  • Table 3: Recent Technological Innovations
  • Table 4: Few Major Inorganic Growth Activities in the Whole Genome and Exome Sequencing Market
  • Table 5: Whole Genome and Exome Sequencing Market (by Region), $Million, 2023-2033
  • Table 6: Europe Whole Genome and Exome Sequencing Market (by End User), $Million, 2023-2033